References

1. Sinha, R.; El-Bayoumy, K. Apoptosis is a critical cellular event in cancer chemoprevention and chemotherapy by selenium compounds. Curr. Cancer Drug Targets 2004, 4, 13–28.
2. Tan, H.W.; Mo, H.-Y.; Lau, A.T.Y.; Xu, Y.-M. Selenium species: Current status and potentials in cancer prevention and therapy. Int. J. Mol. Sci. 2018, 20, 75.
3. Sanmartín, C.; Plano, D.; Sharma, A.K.; Palop, J.A. Selenium compounds, apoptosis and other types of cell death: An overview for cancer therapy. Int. J. Mol. Sci. 2012, 13, 9649–9672.
4. Naithani, R. Organoselenium compounds in cancer chemoprevention. Mini Rev. Med. Chem. 2008, 8, 657–668.
5. Li, G.-X.; Hu, H.; Jiang, C.; Schuster, T.; Lü, J. Differential involvement of reactive oxygen species in apoptosis induced by two classes of selenium compounds in human prostate cancer cells. Int. J. Cancer 2007, 120, 2034–2043.
6. Gasparian, A.V.; Yao, Y.J.; Lü, J.; Yemelyanov, A.Y.; Lyakh, L.A.; Slaga, T.J.; Budunova, I.V. Selenium compounds inhibit IκB Kinase (IKK) and Nuclear Factor-κB (NF-κB) in prostate cancer cells. Mol. Cancer Ther. 2002, 1, 1079–1087.
7. Jiang, C.; Wang, Z.; Ganther, H.; Lü, J. Distinct effects of methylseleninic acid versus selenite on apoptosis, cell cycle, and protein kinase pathways in DU145 human prostate cancer cells. Mol. Cancer Ther. 2002, 1, 1059–1066.
8. Li, G.-x.; Lee, H.-J.; Wang, Z.; Hu, H.; Liao, J.D.; Watts, J.C.; Combs, G.F., Jr.; Lü, J. Superior in vivo inhibitory efficacy of methylseleninic acid against human prostate cancer over selenomethionine or selenite. Carcinogenesis 2008, 29, 1005–1012.
9. Shen, C.L.; Song, W.; Pence, B.C. Interactions of selenium compounds with other antioxidants in DNA damage and apoptosis in human normal keratinocytes. Cancer Epidemiol. Biomarkers Prev. 2001, 10, 385–390.
10. Gopalakrishna, R.; Gundimeda, U. Protein kinase C as a molecular target for cancer prevention by selenocompounds. Nutr. Cancer 2001, 40, 55–63.
11. Rikiishi, H. Apoptotic cellular events for selenium compounds involved in cancer prevention. J. Bioenerg. Biomembr. 2007, 39, 91–98.
12. Zhou, N.; Xiao, H.; Li, T.K.; Nur, E.K.A.; Liu, L.F. DNA damage-mediated apoptosis induced by selenium compounds. J. Biol. Chem. 2003, 278, 29532–29537.
13. De Miranda, J.X.; Andrade, F.d.O.; Conti, A.d.; Dagli, M.L.Z.; Moreno, F.S.; Ong, T.P. Effects of selenium compounds on proliferation and epigenetic marks of breast cancer cells. J. Trace Elem. Med. Biol. 2014, 28, 486–491.
14. Liu, C.; Chen, J.; Wu, Z.; Li, Y.; Zhu, Y.; Ren, Y.; Zhou, Q. Selenium compounds induce ROS in human high-metastatic large cell lung cancer cell line L9981. Zhongguo Fei Ai Za Zhi 2008, 11, 354–358.
15. Shen, H.-M.; Ding, W.-X.; Ong, C.-N. Intracellular glutathione is a cofactor in methylseleninic acid-induced apoptotic cell death of human hepatoma HEPG2 cells. Free Radic. Biol. Med. 2002, 33, 552–561.
16. Soukupová, K.; Rudolf, E. Suppression of proliferation and activation of cell death by sodium selenite involves mitochondria and lysosomes in chemoresistant bladder cancer cells. J. Trace Elem. Med. Biol. 2019, 52, 58–67.
17. Harmanci, D.; Erbayraktar, Z.; Sayin, O.; Guner, G.A. In vitro effects of selenium on human glioblastoma multiforme cell lines: A preliminary study. Acta Clin. Croat. 2017, 56, 48–57.
18. Pang, K.-L.; Chin, K.-Y. Emerging Anticancer Potentials of Selenium on Osteosarcoma. Int. J. Mol. Sci. 2019, 20, 5318.
19. Shigemi, Z.; Manabe, K.; Hara, N.; Baba, Y.; Hosokawa, K.; Kagawa, H.; Watanabe, T.; Fujimuro, M. Methylseleninic acid and sodium selenite induce severe ER stress and subsequent apoptosis through UPR activation in PEL cells. Chem. Biol. Interact. 2017, 266, 28–37.
20. Kim, T.-S.; Yun, B.Y.; Kim, I.Y. Induction of the mitochondrial permeability transition by selenium compounds mediated by oxidation of the protein thiol groups and generation of the superoxide. Biochem. Pharmacol. 2003, 66, 2301–2311.
21. Subburayan, K.; Thayyullathil, F.; Pallichankandy, S.; Cheratta, A.R.; Galadari, S. Superoxide-mediated ferroptosis in human cancer cells induced by sodium selenite. Transl. Oncol. 2020, 13, 100843.
22. Gajdács, M.; Spengler, G.; Sanmartín, C.; Marć, M.A.; Handzlik, J.; Domínguez-Álvarez, E. Selenoesters and selenoanhydrides as novel multidrug resistance reversing agents: A confirmation study in a colon cancer MDR cell line. Bioorg. Med. Chem. Lett. 2017, 27, 797–802.
23. ClinicalTrials.gov. Study Evaluating Sodium Selenite in Combination with Abiraterone in Castrate Resistant Prostate Cancer Progressing on Abiraterone. Available online: (accessed on 7 January 2021).
24. ClinicalTrials.gov. Phase I Sodium Selenite in Combination with Docetaxel in Castration-resistant Prostate Cancer. Available online: (accessed on 7 January 2021).
25. ClinicalTrials.gov. Sodium Selenite and Radiation Therapy in Treating Patients with Metastatic Cancer. Available online: (accessed on 7 January 2021).
26. ClinicalTrials.gov. The Use of Selenium to Treat Secondary Lymphedema—Breast Cancer. Available online: (accessed on 7 January 2021).
27. ClinicalTrials.gov. Sodium Selenite as a Cytotoxic Agent in Advanced Carcinoma (SECAR). Available online: (accessed on 7 January 2021).
28. ClinicalTrials.gov. High Dose Inorganic Selenium for Preventing Chemotherapy Induced Peripheral Neuropathy (SELENIUM). Available online: (accessed on 7 January 2021).
29. Álvarez-Pérez, M.; Ali, W.; Marć, M.A.; Handzlik, J.; Domínguez-Álvarez, E. Selenides and Diselenides: A Review of Their Anticancer and Chemopreventive Activity. Molecules 2018, 23, 628.
30. Brigelius-Flohé, R. Selenium compounds and selenoproteins in cancer. Chem. Biodivers. 2008, 5, 389–395.
31. Nedel, F.; Campos, V.F.; Alves, D.; McBride, A.J.A.; Dellagostin, O.A.; Collares, T.; Savegnago, L.; Seixas, F.K. Substituted diaryl diselenides: Cytotoxic and apoptotic effect in human colon adenocarcinoma cells. Life Sci. 2012, 91, 345–352.
32. Posser, T.; de Paula, M.T.; Franco, J.L.; Leal, R.B.; da Rocha, J.B.T. Diphenyl diselenide induces apoptotic cell death and modulates ERK1/2 phosphorylation in human neuroblastoma SH-SY5Y cells. Arch. Toxicol. 2011, 85, 645–651.
33. Kim, C.; Lee, J.; Park, M.-S. Synthesis of new diorganodiselenides from organic halides: Their antiproliferative effects against human breast cancer MCF-7 cells. Arch. Pharmacal. Res. 2015, 38, 659–665.
34. Krasowska, D.; Iraci, N.; Santi, C.; Drabowicz, J.; Cieslak, M.; Kaźmierczak-Barańska, J.; Palomba, M.; Królewska-Golińska, K.; Magiera, J.; Sancineto, L. Diselenides and benzisoselenazolones as antiproliferative agents and glutathione-s-transferase inhibitors. Molecules 2019, 24, 2914.
35. Nogueira, C.W.; Rocha, J.B. Toxicology and pharmacology of selenium: Emphasis on synthetic organoselenium compounds. Arch. Toxicol. 2011, 85, 1313–1359.
36. Rosa, R.M.; Roesler, R.; Braga, A.L.; Saffi, J.; Henriques, J.A.P. Pharmacology and toxicology of diphenyl diselenide in several biological models. Braz. J. Med. Biol. Res. 2007, 40, 1287–1304.
37. Meinerz, D.F.; Allebrandt, J.; Mariano, D.O.C.; Waczuk, E.P.; Soares, F.A.; Hassan, W.; Rocha, J.B.T. Differential genotoxicity of diphenyl diselenide (PhSe)2 and diphenyl ditelluride (PhTe)2. PeerJ 2014, 2, e290.
38. Stefanello, S.T.; Dobrachinski, F.; de Carvalho, N.R.; Amaral, G.P.; Barcelos, R.P.; Oliveira, V.A.; Oliveira, C.S.; Giordani, C.F.A.; Pereira, M.E.; Rodrigues, O.E.D.; et al. Free radical scavenging in vitro and biological activity of diphenyl diselenide-loaded nanocapsules: DPDS-NCS antioxidant and toxicological effects. Int. J. Nanomed. 2015, 10, 5663–5670.
39. Chagas, P.M.; Bortolatto, C.F.; Wilhelm, E.A.; Nogueira, C.W. High doses of 2,2′-dithienyl diselenide cause systemic toxicity in rats: An in vitro and in vivo study. J. Appl. Toxicol. 2013, 33, 480–487.
40. Savegnago, L.; Jesse, C.R.; Nogueira, C.W. Structural modifications into diphenyl diselenide molecule do not cause toxicity in mice. Environ. Toxicol. Pharmacol. 2009, 27, 271–276.
41. Marcondes Sari, M.H.; Ferreira, L.M.; Zborowski, V.A.; Araujo, P.C.O.; Cervi, V.F.; Brüning, C.A.; Cruz, L.; Nogueira, C.W. p,p’-Methoxyl-diphenyl diselenide-loaded polymeric nanocapsules are chemically stable and do not induce toxicity in mice. Eur. J. Pharm. Biopharm. 2017, 117, 39–48.
42. Dos Santos, E.d.A.; Hamel, E.; Bai, R.; Burnett, J.C.; Tozatti, C.S.S.; Bogo, D.; Perdomo, R.T.; Antunes, A.M.M.; Marques, M.M.; Matos, M.d.F.C.; et al. Synthesis and evaluation of diaryl sulfides and diaryl selenide compounds for antitubulin and cytotoxic activity. Bioorg. Med. Chem. Lett. 2013, 23, 4669–4673.
43. Zhang, L.; Zhou, L.; Du, J.; Li, M.; Qian, C.; Cheng, Y.; Peng, Y.; Xie, J.; Wang, D. Induction of apoptosis in human multiple myeloma cell lines by ebselen via enhancing the endogenous reactive oxygen species production. Biomed Res. Int. 2014, 2014, 696107.
44. Yang, C.F.; Shen, H.M.; Ong, C.N. Protective effect of ebselen against hydrogen peroxide-induced cytotoxicity and DNA damage in HepG2 cells. Biochem. Pharmacol. 1999, 57, 273–279.
45. Gandin, V.; Khalkar, P.; Braude, J.; Fernandes, A.P. Organic selenium compounds as potential chemotherapeutic agents for improved cancer treatment. Free Radic. Biol. Med. 2018, 127, 80–97.
46. Chen, Z.; Lai, H.; Hou, L.; Chen, T. Rational design and action mechanisms of chemically innovative organoselenium in cancer therapy. Chem. Commun. 2020, 56, 179–196.
47. Sharma, V.; Tewari, R.; Sk, U.H.; Joseph, C.; Sen, E. Ebselen sensitizes glioblastoma cells to Tumor Necrosis Factor (TNFalpha)-induced apoptosis through two distinct pathways involving NF-kappaB downregulation and Fas-mediated formation of death inducing signaling complex. Int. J. Cancer 2008, 123, 2204–2212.
48. Thabet, N.M.; Moustafa, E.M. Synergistic effect of Ebselen and gamma radiation on breast cancer cells. Int. J. Radiat. Biol. 2017, 93, 784–792.
49. ClinicalTrials.gov. Study to Evaluate the Safety and Pharmacokinetics of SPI-1005. Available online: (accessed on 7 January 2021).
50. ClinicalTrials.gov. SPI-1005 for Prevention and Treatment of Chemotherapy Induced Hearing Loss. Available online: (accessed on 7 January 2021).
51. Wang, L.; Yang, Z.; Fu, J.; Yin, H.; Xiong, K.; Tan, Q.; Jin, H.; Li, J.; Wang, T.; Tang, W.; et al. Ethaselen: A potent mammalian thioredoxin reductase 1 inhibitor and novel organoselenium anticancer agent. Free Radic. Biol. Med. 2012, 52, 898–908.
52. Tan, Q.; Li, J.; Yin, H.-w.; Wang, L.-h.; Tang, W.-c.; Zhao, F.; Liu, X.-m.; Zeng, H.-h. Augmented antitumor effects of combination therapy of cisplatin with ethaselen as a novel thioredoxin reductase inhibitor on human A549 cell in vivo. Investig. New Drugs 2010, 28, 205–215.
53. ClinicalTrials.gov. Ethaselen for the Treatment of Thioredoxin Reductase High Expression Advanced Non-small Cell Lung Cancers. Available online: (accessed on 27 November 2020).
54. Sinha, I.; Allen, J.E.; Pinto, J.T.; Sinha, R. Methylseleninic acid elevates REDD1 and inhibits prostate cancer cell growth despite AKT activation and mTOR dysregulation in hypoxia. Cancer Med. 2014, 3, 252–264.
55. Zeng, H.; Wu, M. The inhibitory efficacy of methylseleninic acid against colon cancer xenografts in C57BL/6 Mice. Nutr. Cancer 2015, 67, 831–838.
56. Li, Z.; Carrier, L.; Rowan, B.G. Methylseleninic acid synergizes with tamoxifen to induce caspase-mediated apoptosis in breast cancer cells. Mol. Cancer Ther. 2008, 7, 3056–3063.
57. Wang, L.; Bonorden, M.J.L.; Li, G.-x.; Lee, H.-J.; Hu, H.; Zhang, Y.; Liao, J.D.; Cleary, M.P.; Lü, J. Methyl-selenium compounds inhibit prostate carcinogenesis in the transgenic adenocarcinoma of mouse prostate model with survival benefit. Cancer Prev. Res. 2009, 2, 484–495.
58. Sinha, I.; Null, K.; Wolter, W.; Suckow, M.A.; King, T.; Pinto, J.T.; Sinha, R. Methylseleninic acid downregulates hypoxia-inducible factor-1α in invasive prostate cancer. Int. J. Cancer 2012, 130, 1430–1439.
59. Gundimeda, U.; Schiffman, J.E.; Chhabra, D.; Wong, J.; Wu, A.; Gopalakrishna, R. Locally generated methylseleninic acid induces specific inactivation of protein kinase C isoenzymes: Relevance to selenium-induced apoptosis in prostate cancer cells. J. Biol. Chem. 2008, 283, 34519–34531.
60. Cho, S.D.; Jiang, C.; Malewicz, B.; Dong, Y.; Young, C.Y.F.; Kang, K.-S.; Lee, Y.-S.; Ip, C.; Lü, J. Methyl selenium metabolites decrease prostate-specific antigen expression by inducing protein degradation and suppressing androgen-stimulated transcription. Mol. Cancer Ther. 2004, 3, 605–612.
61. Wu, X.; Zhang, Y.; Pei, Z.; Chen, S.; Yang, X.; Chen, Y.; Lin, D.; Ma, R.Z. Methylseleninic acid restricts tumor growth in nude mice model of metastatic breast cancer probably via inhibiting angiopoietin-2. BMC Cancer 2012, 12, 192.
62. Wang, L.; Walia, B.; Evans, J.; Gewirtz, A.T.; Merlin, D.; Sitaraman, S.V. IL-6 Induces NF-κB Activation in the Intestinal Epithelia. J. Immunol. 2003, 171, 3194–3201.
63. Hu, H.; Jiang, C.; Ip, C.; Rustum, Y.M.; Lü, J. Methylseleninic Acid Potentiates Apoptosis Induced by Chemotherapeutic Drugs in Androgen-Independent Prostate Cancer Cells. Clin. Cancer Res. 2005, 11, 2379–2388.
64. Qi, Y.; Fu, X.; Xiong, Z.; Zhang, H.; Hill, S.M.; Rowan, B.G.; Dong, Y. Methylseleninic acid enhances paclitaxel efficacy for the treatment of triple-negative breast cancer. PLoS ONE 2012, 7, e31539.
65. Liu, Y.; Li, W.; Guo, M.; Li, C.; Qiu, C. Protective Role of Selenium Compounds on the Proliferation, Apoptosis, and Angiogenesis of a Canine Breast Cancer Cell Line. Biol. Trace Elem. Res. 2016, 169, 86–93.
66. Lafin, J.T.; Sarsour, E.H.; Kalen, A.L.; Wagner, B.A.; Buettner, G.R.; Goswami, P.C. Methylseleninic acid induces lipid peroxidation and radiation sensitivity in head and neck cancer cells. Int. J. Mol. Sci. 2019, 20, 225.
67. Díaz-Argelich, N.; Encío, I.; Plano, D.; Fernandes, A.P.; Palop, J.A.; Sanmartín, C. Novel methylselenoesters as antiproliferative agents. Molecules 2017, 22, 1288.
68. Khalkar, P.; Díaz-Argelich, N.; Antonio Palop, J.; Sanmartín, C.; Fernandes, A.P. Novel methylselenoesters induce programed cell death via entosis in pancreatic cancer cells. Int. J. Mol. Sci. 2018, 19, 2849.
69. Angeli, A.; Carta, F.; Supuran, C.T. Carbonic anhydrases: Versatile and useful biocatalysts in chemistry and biochemistry. Catalysts 2020, 10, 1008.
70. Delfino, R.T.; Ribeiro, T.S.; Figueroa-Villar, J.D. Organophosphorus compounds as chemical warfare agents: A review. J. Braz. Chem. Soc. 2009, 20, 407–428.
71. Domínguez-Álvarez, E.; Plano, D.; Font, M.; Calvo, A.; Prior, C.; Jacob, C.; Palop, J.A.; Sanmartín, C. Synthesis and antiproliferative activity of novel selenoester derivatives. Eur. J. Med. Chem. 2014, 73, 153–166.
72. Domínguez-Álvarez, E.; Gajdács, M.; Spengler, G.; Palop, J.A.; Marć, M.A.; Kieć-Kononowicz, K.; Amaral, L.; Molnár, J.; Jacob, C.; Handzlik, J.; et al. Identification of selenocompounds with promising properties to reverse cancer multidrug resistance. Bioorg. Med. Chem. Lett. 2016, 26, 2821–2824.
73. Spengler, G.; Gajdács, M.; Marć, M.A.; Domínguez-Álvarez, E.; Sanmartín, C. Organoselenium compounds as novel adjuvants of chemotherapy drugs-a promising approach to fight cancer drug resistance. Molecules 2019, 24, 336.
74. White, E. Entosis: It’s a cell-eat-cell world. Cell 2007, 131, 840–842.
75. Rahden-Staroń, I.; Suchocki, P.; Czeczot, H. Evaluation of mutagenic activity of the organo-selenium compound Selol by use of the Salmonella typhimurium mutagenicity assay. Mutat. Res. Genet. Toxicol. Environ. Mutagen. 2010, 699, 44–46.
76. Jastrzebski, Z.; Czyzewska-Szafran, H.; Fijatek, Z.; Suchocki, P.; Fitak, B.A. Toxicity studies of a new selenium compound, Selol, in rats. Drugs Exp. Clin. Res. 1995, 21, 217–220.
77. Ślusarczyk, J.; Dudek, M.; Wierzbicka, M.; Suchocki, P.; Kuraś, M. Antimitotic effect of Selol and sodium selenate (IV) on Allium test cells. Caryologia 2014, 67, 250–259.
78. Suchocki, P.; Misiewicz-Krzemińska, I.; Skupińska, K.; Niedźwiecka, K.; Lubelska, K.; Fijałek, Z.; Kasprzycka-Guttman, T. Selenitetriglicerydes affect CYP1A1 and QR activity by involvement of reactive oxygen species and Nrf2 transcription factor. Pharmacol. Rep. 2010, 62, 352–361.
79. Sonet, J.; Mosca, M.; Bierla, K.; Modzelewska, K.; Flis-Borsuk, A.; Suchocki, P.; Ksiazek, I.; Anuszewska, E.; Bulteau, A.-L.; Szpunar, J.; et al. Selenized plant oil is an efficient source of selenium for selenoprotein biosynthesis in human cell lines. Nutrients 2019, 11, 1524.
80. Suchocki, P.; Misiewicz, I.; Skupinska, K.; Waclawek, K.; Fijalek, Z.; Kasprzycka-Guttman, T. The activity of Selol in multidrug-resistant and sensitive human leukemia cells. Oncol. Rep. 2007, 18, 893–899.
81. Flis, A.; Suchocki, P.; Królikowska, M.A.; Suchocka, Z.; Remiszewska, M.; Śliwka, L.; Książek, I.; Sitarz, K.; Sochacka, M.; Hoser, G.; et al. Selenitetriglycerides-Redox-active agents. Pharmacol. Rep. 2015, 67, 1–8.
82. Grosicka-Maciąg, E.; Kurpios-Piec, D.; Woźniak, K.; Kowalewski, C.; Szumiło, M.; Drela, N.; Kiernozek, E.; Suchocki, P.; Rahden-Staroń, I. Selol (Se IV) modulates adhesive molecules in control and TNF-α-stimulated HMEC-1 cells. J. Trace Elem. Med. Biol. 2019, 51, 106–114.
83. Sochacka, M.; Giebułtowicz, J.; Remiszewska, M.; Suchocki, P.; Wroczyński, P. Effects of Selol 5% supplementation on the activity or concentration of antioxidants and malondialdehyde level in the blood of healthy mice. Pharmacol. Rep. 2014, 66, 301–310.
84. Dudkiewicz-Wilczyńska, J.; Grabowska, A.; Książek, I.; Sitarz, K.; Suchocki, P.; Anuszewska, E. Comparison of selected gene expression profiles in sensitive and resistant cancer cells treated with doxorubicin and Selol. Contemp. Oncol. 2014, 18, 90–94.
85. Bujalska, M.; Gumułka, S.W. Effect of selenium compound (selol) on the opioid activity in vincristine induced hyperalgesia. Neuro Endocrinol. Lett. 2008, 29, 552–557.